Technology evaluation: Rexin-G, Epeius Biotechnologies.
Published
Journal Article (Review)
Rexin-G is a 'pathotropic', tumor-targeted, injectable retroviral vector carrying a mutant form of the cyclin G1 gene, under development by Epeius Biotechnologies for the potential treatment of metastatic cancer. The therapy is currently undergoing phase I/II clinical trials.
Full Text
Duke Authors
Cited Authors
- Morse, M
Published Date
- April 2005
Published In
Volume / Issue
- 7 / 2
Start / End Page
- 164 - 169
PubMed ID
- 15844625
Pubmed Central ID
- 15844625
International Standard Serial Number (ISSN)
- 1464-8431
Language
- eng
Conference Location
- England